(Q38165247)

30 August 2017

title

c-MET kinase inhibitors: a patent review (2011 - 2013). (English)

1 reference

30 August 2017

Kongkai Zhu

1

1 reference

30 August 2017

Xiangqian Kong

2

1 reference

30 August 2017

Dan Zhao

3

1 reference

30 August 2017

Zhongjie Liang

4

1 reference

30 August 2017

Cheng Luo

5

1 reference

30 August 2017

language of work or name

English

0 references

publication date

25 November 2013

1 reference

Expert Opinion on Therapeutic Patents

30 August 2017

published in

1 reference

30 August 2017

volume

24

1 reference

30 August 2017

issue

2

1 reference

30 August 2017

page(s)

217-230

1 reference

Met, metastasis, motility and more

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Showering c-MET-dependent cancers with drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Molecular cloning of a new transforming gene from a chemically transformed human cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Small molecule c-Met kinase inhibitors: a review of recent patents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Targeting the c-Met signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Structural Basis for Selective Small Molecule Kinase Inhibition of Activated c-Met

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

NK4 gene therapy targeting HGF-Met and angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Discovery of a novel series of quinoxalines as inhibitors of c-Met kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Listeria InlB takes a different route to met.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

A new Met inhibitory-scaffold identified by a focused forward chemical biological screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Developing c-MET pathway inhibitors for cancer therapy: progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Characteristics of lung cancers harboring NRAS mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Novel agents on the horizon for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Cancer: a Systems Biology disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

From 'omics' to complex disease: a systems biology approach to gene-environment interactions in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

Network pharmacology for cancer drug discovery: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.864279

10.1517/13543776.2014.864279

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference